NCT06250400View on ClinicalTrials.gov

Efficacy and Safety of Histamine Human Immunoglobulin in the Treatment of Chronic Spontaneous Urticaria (CSU)

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

252

Participants

Timeline

Start Date

March 31, 2024

Primary Completion Date

July 1, 2025

Study Completion Date

December 31, 2025

Conditions
Chronic Spontaneous Urticaria
Interventions
BIOLOGICAL

human histaglobulin

once 12 mg/2ml/bottle, 2 subcutaneous injection once a week, using 4 times in a row, a total of 28 d;

BIOLOGICAL

placebo

once 12 mg/2ml/bottle, 2 subcutaneous injection once a week, using 4 times in a row, a total of 28 d;

DRUG

Loratadine 10 Mg

orally, 10mg once a day for 4 weeks

All Listed Sponsors
lead

Hangzhou Grand Biologic Pharmaceutical, Inc.

INDUSTRY

NCT06250400 - Efficacy and Safety of Histamine Human Immunoglobulin in the Treatment of Chronic Spontaneous Urticaria (CSU) | Biotech Hunter | Biotech Hunter